VeraBIND™ Tau is a new noninvasive test that offers 96 percent sensitivity and 90 percent specificity, empowering earlier and more accessible Alzheimer's detection
As the frequency of late-stage cancer diagnoses rises, more accurate and efficient screening methods are needed to address overspending and improve early detection outcomes
A new, ultra-fast genetic test developed by NYU Langone Health may enable surgeons to identify cancer cells in real-time during brain surgery, improving tumor removal accuracy
How centralized informatics solutions can eliminate data silos, improve traceability, facilitate compliance, and reduce turnaround time
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.